| Name | Title | Contact Details |
|---|---|---|
Gabriella Silva |
CFO Rotational Financial Analyst | Profile |
Rob Bucenell |
Executive Director, Human Resources | Profile |
Jed Brown |
Senior Director, Clinical Supply Chain Management | Profile |
Lesa Whitehead |
Talent Acquisition | Profile |
Francisca Ekukole |
Director, Human Resources | Profile |
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.
Rafael Holdings is focused on the development of novel cancer therapies. The company is a significant investor in two clinical stage oncology companies, Rafael Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd. Through its wholly owned Barer Institute subsidiary, the company is developing a pipeline of compounds focused on the regulation of cancer metabolism.
Dompé: un impegno costante nella ricerca scientifica per lo sviluppo di farmaci innovativi per migliorare lo stato di salute dell’uomo
Vail Health provides 24/7 hospital, urgent-emergent care, orthopaedics, cardiology, physical therapy, endocrinology, internal medicine, cancer care, childbirth, surgery and plastics.
Brains Bioceutical Corp is a globally recognized leader in GMP-certified production of naturally-sourced Active Pharmaceutical Ingredients (API).